摘要目的:分析血清微小RNA-194(miRNA-194)水平与前列腺癌(PCa)靶向治疗预后的相关性。方法:抽取2018年1月至2019年12月三门峡市中心医院收治的50例前列腺癌患者为研究对象，所有患者均接受甲磺酸阿帕替尼靶向治疗，治疗4个周期后至少随访4周，评估患者近期疗效并分为预后不良组和预后良好组，患者接受靶向治疗前均行血清miRNA-194检测；比较两组基线资料、实验室指标及血清miRNA-194表达，分析治疗前血清miRNA-194表达与前列腺癌靶向治疗患者预后的关系。结果:50例前列腺癌患者经评估，预后不良组12例，占24.00%；预后良好组38例。预后不良组患者血清前列腺特异性抗原(PSA)、miRNA-194水平高于预后良好组( P<0.05)；绘制受试者工作曲线(ROC)结果显示，治疗前血清miRNA-194高表达预测前列腺癌靶向治疗患者预后不良风险AUC为0.887，预测价值较理想。 结论:治疗前血清miRNA-194高表达与前列腺癌靶向治疗患者预后不良有关，对预测前列腺癌靶向治疗患者预后不良风险有一定价值。

abstractsObjective:To analyze the correlation between serum microRNA-194 (miRNA-194) level and prognosis of targeted therapy for prostate cancer (PCa) .Methods:A total of 50 PCa patients admitted to Sanmenxia Central Hospital from January 2018 to December 2019 were selected as the study subjects, all patients received targeted therapy with apatinib mesylate, followed up for at least 4 weeks after 4 cycles of treatment, the short-term efficacy of patients was evaluated as short-term prognosis observation index and divided into poor prognosis group and good prognosis group, the serum miRNA-194 of patients was detected before targeted therapy; the baseline data, laboratory indexes and serum miRNA-194 expression between the two groups were compared, the relationship between serum miRNA-194 expression and prognosis of PCa patients after targeted therapy was mainly analyzed.Results:Among the 50 patients with PCa after evaluation, 12 patients were included into the poor prognosis group, accounting for 24.00%; 38 cases were included into the good prognosis group.The serum prostate specific antigen and miRNA-194 levels of patients in the poor prognosis group were higher than those in the good group ( P<0.05); the receiver characterist operating curve (ROC) was drawn, the results showed that the AUC of high expression of serum miRNA-194 before treatment predicted the risk of poor prognosis of PCa patients after targeted therapy was 0.887, the predictive value was ideal. Conclusions:The high expression of serum miRNA-194 before treatment is related to poor prognosis of PCa patients after targeted therapy, which has certain value in predicting the risk of poor prognosis in PCa patients after targeted therapy.